Ecopro BM Reports Q4 Turnaround to Profit, Up 12% YoY - (ECP)

Ecopro Biologics (ECP) reported a significant operational turnaround in Q4 2025, posting a net profit of $18.7 million, a 12% increase from the prior-year period. Revenue rose 15% to $219.3 million, driven by strong demand for its biologics and improved pricing. The company attributed the improvement to streamlined operations and higher utilization of its manufacturing capacity. CEO Dr. Michael Chen stated, "We are on track to achieve our full-year guidance, with continued momentum expected in the first quarter."